|
GB9622660D0
|
|
Immunogenic detoxified mutant toxin
|
|
GB9603314D0
|
|
Immunogenic detoxified mutant toxins
|
|
GB9517926D0
|
|
Binding protein
|
|
WO9609757A1
|
|
Mouse model for helicobacter pylori infection
|
|
GB9513371D0
|
|
Immunogenic detoxified mutant toxins
|
|
GB9506251D0
|
|
Mouse model for helicobacter pylori infection
|
|
AU1278595A
|
|
Non-toxic mucosal adjuvant
|
|
GB9422331D0
|
|
H. pylori fermentation process
|
|
GB9422096D0
|
|
Combined meningitis vaccine
|
|
GB9422095D0
|
|
Combined meningitis vaccine
|
|
GB9419661D0
|
|
Mouse model for helicobacter pylori infection
|
|
GB9416657D0
|
|
T cell activation
|
|
GB9416671D0
|
|
Assay
|
|
US5629167A
|
|
Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
|
|
EP0654999A1
|
|
Use of inhibitors of vacuolar-type h?+ atpases
|
|
SG48353A1
|
|
Helicobacter pylori proteins useful for vaccines and diagnostics
|
|
CA2127091A1
|
|
Immunogenic Detoxified Mutants of Cholera Toxin and of the Toxin LT, Their Preparation and Their Use for the Preparation of Vaccines
|
|
EP0522291A1
|
|
Process for purifying hepatitis a virus (HAV), virus thus purified and vaccine compositions containing it
|
